8-K filing — Apnimed, Inc. (APMD)

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apnimed, Inc. announced the issuance of equity-based inducement grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight

The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.

Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M

LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.

Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.